Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433600 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| SCHEMBL16932314 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| SCHEMBL26117461 | 0.90 | CTSC (1.00) | CTSCKCNH2 | |
| SCHEMBL16932303 | 0.90 | CTSC (1.00) | CTSCKCNH2 | |
| SCHEMBL29433607 | 0.90 | CTSC (1.00) | CTSCKCNH2 | |
| SCHEMBL23700760 | 0.86 | CTSC (1.00) | CTSCKCNH2 | |
| SCHEMBL29433643 | 0.86 | CTSC (1.00) | CTSCKCNH2 | |
| SCHEMBL16932316 | 0.86 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL19813196 | 0.85 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL30901221 | 0.85 | CTSC (1.00) | CTSCKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118159525-A | Specific N- (1-cyano-2-phenethyl) -1, 4-oxaazepane-2-carboxamides for the treatment of chronic sinusitis | 英斯梅德股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-116157687-A | Methods for extracting neutrophil serine protease and treating dipeptidyl peptidase 1 mediated disorders | 英斯梅德股份有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-118159525-A | Specific N- (1-cyano-2-phenethyl) -1, 4-oxaazepane-2-carboxamides for the treatment of chronic sinusitis | 英斯梅德股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-112055593-B | Pharmaceutical composition | 阿斯利康(瑞典)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-116437919-B | Methods of treating metastasis with cathepsin C inhibitors | 中国科学院上海营养与健康研究所 | 2024-04-02 | — | — | CN | disclosed |
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-10-03 | — | — | US | disclosed |
| CN-110483492-B | Dipeptidyl peptidase I inhibitors | 阿斯利康(瑞典)有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116437919-A | Methods of treating metastasis with cathepsin C inhibitors | 中国科学院上海营养与健康研究所 | 2023-07-14 | — | — | CN | disclosed |
| US-11667615-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| CN-116157687-A | Methods for extracting neutrophil serine protease and treating dipeptidyl peptidase 1 mediated disorders | 英斯梅德股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20210238152-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | BIOPHARMA CREDIT PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| CN-112055593-A | Pharmaceutical compositions comprising (2S) -N- { (1S) -1-cyano-2- [4- (3-methyl-2-oxo-2, 3-dihydro-1, 3-benzoxazol-5-yl) phenyl ] ethyl } -1, 4-oxazepan-2-carboxamide | 阿斯利康(瑞典)有限公司 | 2020-12-08 | — | — | CN | disclosed |
| EP-3323814-B1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2020-05-13 | — | — | EP | disclosed |
| EP-3323814-A1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | AstraZeneca AB (SE) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773069-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CTSC 7/4885KCNH2 2475/4885 |
| US-11667615-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CTSC 7/4885KCNH2 2475/4885 |
| US-20210238152-A1 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP4, DPP7, DPEP1 | CTSC 7/4885KCNH2 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.